Tiziana Life Sciences Ltd
Develops immunotherapies for neurodegenerative and neuroinflammatory diseases.
TLSA | US
Overview
Corporate Details
- ISIN(s):
- BMG889121031 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON, ENGLAND
Description
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Tiziana Life Sciences Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Tiziana Life Sciences Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Tiziana Life Sciences Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
